> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Polar Capital Holdings Reports 5.19% Of Xenon Shares With A Passive-Control Certification
- URL: https://www.bullished.co/polar-capital-holdings-reports-5-19-of-xenon-shares-with-a-passive-control-certification-fa04f295/
- Published: 2026-11-16T15:01:59.000Z
- Updated: 2026-11-16T15:01:59.000Z
- Description: The holding company and investment adviser Polar Capital LLP each reported the same 5,022,084-share position.
- Author: Matteo Parrino
- Tags: SEC Filings, XENE, Industry: Healthcare

Polar Capital Holdings reported Monday a [5.19% stake](https://www.sec.gov/Archives/edgar/data/0001837309/000117266126005106/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Xenon Pharmaceuticals](https://www.bullished.co/tag/xene/), which develops drugs for neurological and psychiatric disorders. Its SEC passive ownership disclosure put the position at 5,022,084 common shares as of September 30.

## The Same Position, Two Reporting Entities

Polar Capital LLP, the investment adviser named in the disclosure, reported the same share count and ownership percentage as Polar Capital Holdings. Each entity reported sole voting power over 5,022,084 shares.

Both certified that the shares were bought and held for ordinary business purposes, without a purpose or effect of changing or influencing Xenon's control.

The ownership percentage used [96,840,432 outstanding shares](https://www.sec.gov/Archives/edgar/data/0001837309/000117266126005106/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co), the count Xenon reported in its August 6, 2026, quarterly filing.

## Azetukalner Leads Xenon's Drug Pipeline

Xenon's main experimental drug, azetukalner, is in late-stage studies for epilepsy, major depressive disorder and bipolar depression. Its earlier-stage work includes potential drugs for pain and Dravet syndrome, a form of epilepsy.

Xenon also licenses drug-development rights to Neurocrine Biosciences through a collaboration that pays milestones and royalties. Xenon received a $7.5 million milestone payment in February 2025.

As of December 31, 2025, Xenon owned, co-owned or licensed 22 issued U.S. patents and had more than 295 patent applications pending. Its market value was $4.0 billion as of 9:59 a.m. ET Monday.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — Polar Capital Holdings Plc re: Xenon Pharmaceuticals Inc. (XENE)](https://www.sec.gov/Archives/edgar/data/0001837309/000117266126005106/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR

### More on Xenon Pharmaceuticals

- [Xenon Puts Psychiatry Development To The Test With December Depression Results](https://www.bullished.co/xenon-puts-psychiatry-development-to-the-test-with-december-depression-results-1e803e8b/)
- [Xenon's Loss Widens To $110.4 Million As Azetukalner Trials And Launch Preparations Cost More](https://www.bullished.co/xenons-loss-widens-to-110-4-million-as-azetukalner-trials-and-launch-preparations-cost-a141b2a2/)
- [T. Rowe Price Investment Management Reports 8.2% Position In Xenon Without Seeking Control](https://www.bullished.co/t-rowe-price-investment-management-reports-8-2-position-in-xenon-without-seeking-control-2af5f6b0/)

[All Xenon Pharmaceuticals (XENE) coverage →](https://www.bullished.co/tag/xene/)